Compare AstraZeneca plc (AZN) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Fiverr International Ltd — how do they compare? AstraZeneca plc trades at $169.38 (market cap $253.13B), while Fiverr International Ltd trades at $11.45 (market cap $397.97M). The key difference: AstraZeneca plc is far larger — about 636.1× Fiverr International Ltd's market cap, and AstraZeneca plc pays a 1.92% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| AZN | FVRR | |
|---|---|---|
Market Cap | $253.13B | $397.97M |
Sector | Health | Industrials |
52-Week High | $209.48 | $26.67 |
52-Week Low | $137.44 | $9.62 |
Enterprise Value | $279.37B | $128.57M |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Fiverr International (FVRR) trades at $11.27, up 2.08% today, with a bullish technical signal from moving averages. Revenue grew to $430.91M in 2025, with net income reaching $20.98M and a 4.86% margin. The stock appears undervalued with a P/E of 14.64 and P/S of 0.97. Recent news highlights Fiverr's upcoming Q2 2026 earnings and a surge in demand for AI coding specialists, though the stock remains near its 52-week low, down 66% from its high.
The outlook is mixed: strong profitability metrics and low valuation ratios present a potential opportunity, but risks include declining active buyers, ongoing legal investigations, and volatile cash flows. Analyst consensus leans neutral with 41% buy ratings, suggesting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
